Skip to content
This GLP
← Research
Evidence

Significant, and one tenth of noticeable

Sleepiness improved by 0.20 points on a scale where two points is the smallest change anyone can feel. The authors point it out themselves.

Ruth Alvarez7 min read
Daytime sleepiness, Epworth points improvedmeasured effect0.20 pointsnoticeable2 points95% CI 0.14 to 0.26 — precisely measured, and invisibleBreathing events fell 15.28 an hour in the same analysis.

There is a number in this paper that is statistically significant, measured with an interval so narrow you could not ask for better precision, and completely invisible to the person it was measured in — and the authors say so themselves, in the abstract, which is rarer than it should be.

What was pooled

Fifteen studies covering 1,877 participants with moderate to severe obstructive sleep apnea, comparing SGLT2 inhibitors, GLP-1 drugs and aerobic exercise against each other and against placebo. [1] Thirteen of the fifteen are randomized trials; two are case-control studies, which is a weaker foundation than a network meta-analysis usually rests on, and every indirect comparison inherits that weakness.

On the outcome that matters most, GLP-1 drugs did well: breathing events fell by 15.28 an hour against placebo, 95% CI 8.35 to 22.22 — a large effect, consistent with what the dedicated apnea trial found. Body mass index fell 1.78 kg/m2 and average overnight oxygen saturation rose 0.40%.

The number that is not there

Daytime sleepiness is scored on the Epworth scale, and the pooled improvement was 0.20 points, 95% CI 0.14 to 0.26.

The smallest change on that scale a person actually notices — the minimal clinically important difference — is two points. The measured effect is a tenth of that, and the interval is tight enough to say with confidence that the true effect is also about a tenth of that.

The ranking the authors disown

GLP-1 drugs came out top on breathing events, body mass index and oxygen saturation under a statistical ranking method that scores each treatment across the network. The authors then say the comparisons between active treatments were largely non-significant, rested on indirect evidence, and carried certainty that was moderate at best and low or very low for most pairings, so the hierarchy should be read as hypothesis-generating rather than as a basis for recommendations.

That is an unusual thing for a paper to write about its own headline result, and it is the correct thing, for the same reason a pooled count of studies overstates what has been independently observed. A ranking assembled from thin indirect comparisons will still produce a first place.

What to carry away

That a drug can genuinely fix the thing a machine measures and barely move the thing you feel, and that both facts can appear in one paper without either being wrong.

Also that aerobic exercise sat in this network as a comparator and costs nothing, which does not make it equivalent and is worth noticing before a table of treatments starts looking like a shopping list — the habit that reading any ranked table calls for.

Frequently asked

Do GLP-1 drugs help sleep apnea?
On the measured breathing, substantially: 15.28 fewer events an hour against placebo, 95% CI 8.35 to 22.22. On daytime sleepiness, by 0.20 points on a scale where two points is the smallest noticeable change.
What is a minimal clinically important difference?
The smallest change patients report actually feeling. It is the threshold that separates a result being real from a result being worth anything to the person in it.
Did the analysis rank the treatments?
Yes, with GLP-1 drugs on top for breathing events, body mass index and oxygen saturation. The authors describe that hierarchy as hypothesis-generating, with most comparisons carrying low or very low certainty.
What was included?
Fifteen studies and 1,877 participants — thirteen randomized trials and two case-control studies, which is weaker evidence than a network meta-analysis normally pools.

Sources

  1. [1] Zheng J, et al. (2026). Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis Frontiers in Endocrinology. PMID 42676363

Where to get it

Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

Compare providers →

More in Evidence